Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
S SENSORY ORGANS
S01 OPHTHALMOLOGICALS
S01B ANTIINFLAMMATORY AGENTS
S01BC Antiinflammatory agents, non-steroids
S01BC10 Nepafenac
D05143 Nepafenac (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Ophthalmic Agents
Ophthalmic Anti-inflammatories
Nonsteroidal Anti-Inflammatory Drugs, Ophthalmic
Nepafenac
D05143 Nepafenac (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
13 Agents affecting sensory organs
131 Ophthalmic agents
1319 Others
D05143 Nepafenac (JAN/USAN/INN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01504 Nonsteroidal anti-inflammatory drug (NSAID)
DG01906 Anti-inflammatory drug, acetic acid derivatives
D05143 Nepafenac
Drug classes [BR:br08332]
Anti-inflammatory
DG01504 Nonsteroidal anti-inflammatory drug (NSAID)
D05143 Nepafenac
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Prostaglandin synthase
PTGS1 (COX1)
D05143 Nepafenac (JAN/USAN/INN) <JP/US>
PTGS2 (COX2)
D05143 Nepafenac (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05143
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05143
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D05143
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05143